# EAVE II Analysis Repository
## Covid-breakthrough-post-first-booster

### Paper Details
> **Title:** Severe COVID-19 outcomes post full vaccination of primary schedule and boosters: A pooled-analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland and Wales 
>
>**DOI:** 
>
>**Paper authors:** 
>
>**Data source:** not publically available

### Funding
This work was funded by the National Core Studies Immunity group. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20060), with support from the DaC-VaP-2 study also funded by UK Research and Innovation (grant ref MC_PC_20058). Use of national linked healthcare, serology and viral genomic data to identify and characterise post-third and -booster dose vaccine breakthroughs at a population level’ study is a partnership between University of Edinburgh, Swansea University, Oxford University, Queen’s University of Belfast, University of St Andrews and The Office for National Statistics. The authors would like to acknowledge all other project collaborators not involved in these analyses but contributing to wider discussions and preceding outputs. EAVE II is funded by the Medical Research Council (MR/R008345/1) with the support of BREATHE - The Health Data Research Hub for Respiratory Health [MC_PC_19004], which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. Additional support has been provided through Public Health Scotland and Scottish Government DG Health and Social Care. We thank Dave Kelly from Albasoft Ltd for his support with making primary care data available and James Pickett, Wendy Inglis-Humphrey, Vicky Hammersley, Maria Georgiou, Laura Gonzalez Rienda, Pam McVeigh, Amanda Burridge, Sumedha Asnani-Chetal, and Afshin Dastafshan for their support with project management and administration. We acknowledge the support of the EAVE II Patient Advisory Group. Patients and practice of the RSC who allow data sharing, EMIS, TPP, Cegedim, and Wellbeing for help with pseudonymised data extract. Rachel Byford and the ORCHID data team extracted these data, Sneha Anand project managed. The authors would like to acknowledge the help provided by the staff of the Honest Broker Service (HBS) within the Business Services Organisation Northern Ireland (BSO). The HBS is funded by the BSO and the Department of Health for Northern Ireland. The authors alone are responsible for the interpretation of the data and any views or opinions presented are solely those of the author and do not necessarily represent those of the BSO.

